To evaluate, optimize and develop more sensitive non-sputum-based diagnostics for children < 5 years of age applicable at POC and propose an enhanced reference standard that can be applied to unconfirmed as well as confirmed TB

A cross sectional study of children and adolescent aged 6-19 years living with HIV and receiving ART to determine the prevalence of MetS among children and adolescents living with HIV in Uganda, and to identify risks factors for the development of MetS in children and adolescents living with HIV

Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis (PrEP) for primary HIV prevention during pregnancy and postpartum in adolescents and young women and their Infants.

Baylor-Uganda is part of this ongoing multi-centre parallel, observational cohort study among HIV-uninfected pregnant adolescents and young women (aged 16-24) since March 2019. The study is designed to characterize adherence over time among women who initiate once daily oral PrEP during pregnancy and continue in the first 6 months following delivery. It will also compare pregnancy outcomes among women who take PrEP and women who decline PrEP during the antenatal period. More information about the study can be found here;

This is a phase III randomised open-label clinical trial assessing virologic efficacy and safety of Dolutegravir-containing versus Efavirenz-containing ART regimens in HIV-1 infected pregnant women and their infants. Read more
Baylor-Uganda is participating in a multi-country “VESTED” (Virologic Efficacy and Safety of ART Combinations with TAF/TDF, EFV, and DTG) study that is comparing the safety and virologic efficacy of different antiretroviral therapy (ART) regimens during pregnancy and through 50 weeks of maternal and infant follow-up postpartum. HIV-1-infected pregnant women are initiated on either a Dolutegravir-containing or an Efavirenz-containing antiretroviral regimen at 14-28 weeks of gestation. For more details follow the link:

Primary results presented at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI) showed that;
• DTG-containing treatment regimens started at 14-28 weeks of pregnancy are safe and more effective for viral suppression during pregnancy than an EFV-containing regimen.
• These findings re-affirm current international recommendations for use of DTG among all populations, including pregnant women and people of childbearing potential.
• TAF appears to be safer than and as effective as TDF, in combination with DTG and FTC.
Details of the primary results can be found here:

Compares safety and antiretroviral effect of current standard ART to once daily intergrase inhibitor (INSTI) administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed children.

This ongoing two arm, phase 2/3 multi-centre, open label randomized study that started in April 2019 at the Baylor-Uganda COE HIV clinic is sponsored by PENTA Foundation and aims to maintain HIV viral suppression with once daily dolutegravir +darunavir/ritonavir (DTG/DRV/RTV) in children. This dual therapy strategy which combines boosted protease inhibitor (bPI) plus integrase inhibitor (INSTI) could be an excellent choice for switching children that are virally suppressed from NRTIs and NNRTI-based regimens to reduce drug toxicity while maintaining viral suppression with life-long ART. For more details